These findings indicate that ZFAS1 promotes the upregulation of HIF1α through the activation of STAT3. The elevated levels of HIF1α and its downstream targets suggest enhanced glycolytic activity, which may contribute to the metabolic reprogramming and drug resistance observed in CML cells. Here, ZFAS1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.